Idogen's IDO 8 granted orphan drug designation in the USA - Idogen
Investors Home
Board and Advisors | Ambulero
Idogen - Times Square - Idogen
Idogen AB Interim report Idogen AB Interim report
Annual Report
Idogen files patent application for new tolerogenic cell therapy
40/20 – Information regarding the rights issue from Idogen AB
Idogen AB (publ) kommenterar handelsstoppet den 25 april 2019 - Idogen
niklas wallett - Idogen
Idogen appoints Anders Karlsson as new CEO - Idogen
Idogen AB Interim report
ANNUAL REPORT
Idogen publishes Year-end report for 2020
Idogen's Historical Milestones - Idogen
Idogen Year end report 3 - Idogen
Idogen%20Q1%20ENG - Idogen
Idogen extends the project portfolio to projects in autoimmune diseases - Idogen
PRESS RELEASE IDOGEN AB
Idogen's cell technology successfully advanced to large-scale production - Idogen
Idogen aktieägargrupp | Facebook
Annual Report
Idogen AB (publ) Org nr
Stories: EIC-funded company Idogen starts trading on Nasdaq First North Growth Market | EIC Community
Idogen's Historical Milestones - Idogen
